News
Diovan Approved for Younger Patients With Hypertension
The approval was based on data from 3 clinical studies that assessed the antihypertensive effect of valsartan in 290 children 1 to less than 6 years of age.
Your search for hypertension returned 645 results
News
Ponvory Now Available for Relapsing Forms of Multiple Sclerosis
Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 modulator.
Drugs in the Pipeline, News
Trial Evaluating Dapagliflozin in Hospitalized COVID-19 Patients Misses Endpoints
The DARE-19 trial evaluated dapagliflozin in addition to standard of care in reducing disease progression, clinical complications and all-cause mortality in 1250 adults hospitalized with COVID-19.
News
Review Examines Metabolic, Cardiovascular Side Effects of Second-Generation Antipsychotics
A systematic review examined the metabolic and cardiovascular adverse effects in commonly prescribed second-generation antipsychotics.
News
Sarclisa Plus Carfilzomib and Dexamethasone Approved for Relapsed/Refractory Multiple Myeloma
The approval is supported by data from the multicenter, randomized, open-label phase 3 IKEMA trial.
News
Tyvaso Approved for Pulmonary Hypertension With Interstitial Lung Disease
The sNDA approval is supported by data from the phase 3 INCREASE study that evaluated Tyvaso inhalation solution in 326 adults with PH-ILD.
Safety Alerts and Recalls
Antihypertensive Medication Recalled Due to Label Mix-Up
Telmisartan, an angiotensin II receptor blocker, is indicated for the treatment of hypertension.
News
Tongue-Delivered Neuromodulation Therapy Gets FDA Clearance for MS-Related Gait Deficit
PoNS is a portable, noninvasive, prescription-only device intended to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older.
Safety Alerts and Recalls
FDA: Abuse/Misuse of OTC Nasal Decongestant Can Lead to Major Health Complications
Since January 1, 2000, there have been 460 documented cases of propylhexedrine abuse or misuse reported to US poison control centers.
News
FDA-Approved VEGFR Tyrosine Kinase Inhibitors Ranked by Cardiotoxic Potential
Lenvatinib was associated with the most significant probability of producing all grades of cardiovascular injury and hypertension.
